Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repaymentsWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2018 - 2025)

BridgeBio Pharma recorded quarterly Long-Term Debt Repayments of $459.0 million in Q1 2025, down 3.05% quarter-over-quarter from $473.4 million in Q1 2024, and down 3.05% year-over-year from $473.4 million in Q1 2024.

BridgeBio Pharma's Long-Term Debt Repayments history runs 5 years deep, the most recent figure standing at $459.0 million for Q1 2025.

  • In Q1 2025, Long-Term Debt Repayments fell 3.05% year-over-year to $459.0 million; the TTM figure through Jun 2025 stood at $459.0 million (down 3.05% YoY), while the FY2024 annual figure was $473.4 million, changed N/A from the prior year.
  • Long-Term Debt Repayments came in at $459.0 million for Q1 2025 at BridgeBio Pharma, down from $473.4 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $473.4 million in Q1 2024 to a low of $8000.0 in Q2 2021.
  • A 3-year average of $259.6 million and a median of $282.5 million in 2021 frame the typical range for Long-Term Debt Repayments.
  • On a YoY basis, Long-Term Debt Repayments climbed as much as 3.05% in 2025 and fell as far as 3.05% in 2025.
  • BridgeBio Pharma's Long-Term Debt Repayments stood at $106.0 million in 2021, then surged by 346.57% to $473.4 million in 2024, then declined by 3.05% to $459.0 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $459.0 million, $473.4 million, and $106.0 million for Q1 2025, Q1 2024, and Q4 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 BridgeBio Pharma 12.91 Bn 11.98 Bn 184.58 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 459.00 Mn
Mar 31, 2025 459.00 Mn
Mar 31, 2024 473.42 Mn
Mar 31, 2024 473.42 Mn
Dec 31, 2021 106.01 Mn
Dec 31, 2021 106.01 Mn
Jun 30, 2021 8,000.00
Jun 30, 2021 8,000.00
Mar 31, 2019 179,000.00
Mar 31, 2019 179,000.00
Dec 31, 2018 441,000.00
Dec 31, 2018 441,000.00